Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preservative-free brimonidine versus Alphagan in open-angle glaucoma or ocular hypertension
2013-003083-31Phase 3Completed
- Sponsor
- OmniVision
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of brimonidine in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by OmniVision. Primary endpoint: Average diurnal intraocular pressure decrease from baseline to week 4. Started Aug 2013; status: completed.
02
Drugs
brimonidine
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2013-003083-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003083-31.